Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:

NCT ID: NCT02013804 Completed - Clinical trials for Advanced Malignancies

A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

Start date: December 19, 2013
Phase: Phase 1
Study type: Interventional

This is a multicenter, open label, first-in-human dose-escalation study of MEDI0680 (AMP-514) to evaluate the safety, tolerability, PK, immunogenicity (IM), and antitumor activity in adult subjects with solid tumors.

NCT ID: NCT01930006 Completed - Clinical trials for Advanced Malignancies

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

Start date: August 2013
Phase: Phase 1
Study type: Interventional

In this study two MGCD265 oral formulations at dose level of 100 mg are administered to healthy male and female subjects under fasting conditions.

NCT ID: NCT01284192 Completed - Solid Tumor Clinical Trials

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Start date: December 2010
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors and B-cell lymphoma).

NCT ID: NCT00955084 Completed - Clinical trials for Advanced Malignancies

Maintenance Study on the Long Term Safety of XL999

Start date: August 2008
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999. The secondary objectives of this study are as follows: - To evaluate tumor response after long term repeat administration of XL999 in two subjects rolled over from other XL999 studies. - To characterize the long term safety and tolerability of XL999 after repeat administration in two subjects rolled over from other XL999 studies. - To characterize the long term effects of XL999 on cardiac function after repeat administration in two subjects rolled over from other XL999 studies.

NCT ID: NCT00948961 Completed - Clinical trials for Advanced Malignancies

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Start date: September 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.

NCT ID: NCT00779428 Completed - Clinical trials for Advanced Malignancies

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to provide treatment to patients who have participated on a prior protocol investigating Tanespimycin (KOS-953,17-AAG)

NCT ID: NCT00741403 Completed - Lymphoma Clinical Trials

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Start date: August 2008
Phase: Phase 1
Study type: Interventional

An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients The objectives of this study are: - To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks. - To determine pharmacokinetics of CPI-613 following intravenous (IV) administration. - To observe the anti-tumor effects of CPI-613, if any occur.

NCT ID: NCT00679133 Completed - Clinical trials for Advanced Malignancies

Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

Start date: April 2008
Phase: Phase 1
Study type: Interventional

In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days on / 7 days off schedule to patients with advanced malignancies to study its safety profile.

NCT ID: NCT00676299 Completed - Pharmacokinetics Clinical Trials

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess JNJ-26483327 (a drug in development for cancer) for the safety of the drug in patients with advanced solid tumors that have not responded or are no longer responding to available therapies. The absorption, breakdown and elimination of the drug will also be studied.

NCT ID: NCT00651664 Completed - Clinical trials for Advanced Malignancies

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Start date: October 22, 2007
Phase: Phase 1
Study type: Interventional

This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma).